ERBB2 c.35T>G ;(p.L12R)

Variant ID: 17-37856526-T-G

NM_004448.2(ERBB2):c.35T>G;(p.L12R)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Biomolecules
Shin, Jung Won JW; Kim, Soohyun S; Ha, Suji S; Choi, Byungsan B; Kim, Seongyeong S; Im, Seock-Ah SA; Yoon, Tae-Young TY; Chung, Junho J
Publication Date: 2019-10-19

Variant appearance in text: HER2: L12R
PubMed Link: 31635022
Variant Present in the following documents:
  • Main text
  • biomolecules-09-00629.pdf
View BVdb publication page



HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.

Cancer Science
Wang, Tonghui T; Xu, Ye Y; Sheng, Shuyan S; Yuan, Hua H; Ouyang, Tao T; Li, Jinfeng J; Wang, Tianfeng T; Fan, Zhaoqing Z; Fan, Tie T; Lin, Benyao B; Xie, Yuntao Y
Publication Date: 2017-04

Variant appearance in text: HER2: L12R
PubMed Link: 28164408
Variant Present in the following documents:
  • CAS-108-671.pdf
View BVdb publication page